The use of ciprofloxacin in children with psychotic disorders has been investigated, but its use in children without these disorders has not been well established. This study aimed to investigate the effect of ciprofloxacin in children with psychotic disorders and to assess its possible effects on the sleep of children with schizophrenia. The study was conducted at the Department of Child Health and Development, School of Medicine, University of Gothenburg (UIG) and was approved by the Research Ethics Committee of UIG. This was reviewed and approved by the Committee of Medical Sciences at UIG.
Children ages 3 years and older with schizophrenia received ciprofloxacin (250 mg every 8 hours) and/or a placebo for 12 weeks. The study was conducted in accordance with the Declaration of Helsinki and the study protocol was followed. All participants were assessed for their height and weight. Participants were also evaluated for the presence of psychotic disorder, and the children were asked to report on their ability to sleep and to gain and stay awake. Blood samples were taken in the morning and night for the study period. The sleep patterns, daytime sleepiness (DS), and subjective sleep quality (SSQ) were assessed by using the Mini-International Neuropsychiatric Interview (MINI) at 6 and 12 months, and the Hamilton-Norwood Rating Scale for Sleep (HORT) at 6 months. The sleep efficiency and sleep disturbance index (SADI) and the total sleep time (TST) were measured by using the Pittsburgh Sleep Scale and the Pittsburgh Sleep Index. The sleep of the children was measured with the Pittsburgh Sleep Index (SHI) and the Pittsburgh Sleep Index Plus (PSI), and the HORT was used to measure sleep quality. The mean of the two measures was used for statistical analysis.
The children were enrolled and recruited between January 2000 and December 2017 in the UIG and UIG-GIR. All participants were given a written informed consent. The study was registered on the Clinical Trial Register (Clinicaltrials.gov identifier NCT01128834).
The study protocol was approved by the UIG and UIG-GIR. The children were given the written informed consent. They were monitored and observed regularly for sleep, and the data collected from the study period was used for the analysis.
The study protocol was carried out in accordance with the Declaration of Helsinki and the study protocol was reviewed and approved by the Committee of Medical Sciences at UIG.
The study was conducted in the outpatient department of UIG, the Department of Child Health and Development, School of Medicine, University of Gothenburg (UIG), in Gothenburg, Sweden. Inclusion criteria were children aged 3 years and older with schizophrenia who were diagnosed by a psychiatrist and were treated with ciprofloxacin. Inclusion criteria were children with schizophrenia who had received ciprofloxacin for at least 3 months. The study was approved by the Research Ethics Committee of UIG. The children were recruited from the outpatient department of UIG and the Department of Child Health and Development, School of Medicine, University of Gothenburg, Sweden. All participants were recruited from children who received ciprofloxacin for 3 months or longer.
Participants were randomly assigned to the group receiving ciprofloxacin or a placebo (1 mg/kg) for 12 weeks. The study was conducted in compliance with the Declaration of Helsinki and the study protocol was followed. The sleep efficiency and sleep disturbance index (SADI and SSSI) were assessed as the main and secondary outcomes. The SADI was measured by the Pittsburgh Sleep Index (PHI), the Pittsburgh Sleep Index Plus (PSI), the Pittsburgh Sleep Index, the Pittsburgh Sleep Index Plus Plus (PSI Plus), and the Pittsburgh Sleep Index. The HORT was measured using the Pittsburgh Sleep Index and the Pittsburgh Sleep Index Plus, and the HORT was used to measure sleep quality.
The sleep efficiency and sleep disturbance index (SEDI) and the SSSI were assessed as the main and secondary outcomes. The SADI was assessed using the Pittsburgh Sleep Index, the Pittsburgh Sleep Index Plus, the Pittsburgh Sleep Index Plus Plus, and the Pittsburgh Sleep Index Plus Plus Plus. The HORT was assessed using the Pittsburgh Sleep Index Plus and the HORT plus the Pittsburgh Sleep Index Plus. The SSSI was assessed using the Pittsburgh Sleep Index and the HORT plus the Pittsburgh Sleep Index Plus Plus.
Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. Infections may include urinary tract infection, prostatitis, lower respiratory tract infection, otitis media (middle ear infection), sinusitis, skin, bone and joint infections, infectious diarrhea, typhoid fever, and gonorrhea.
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones. History or risk of QT prolongation; known history of myasthenia gravis. Concomitant use with tizanidine.
Vomiting, Stomach pain, Nausea, Diarrhea
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, or lower seizure threshold; history or risk factors for QT interval prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. heart failure, MI, bradycardia); positive family history of aneurysm disease, pre-existing aortic aneurysm or dissection and its risk factors (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, hypertension, peripheral atherosclerotic vascular disease); diabetes, previous tendon disorder (e.g. rheumatoid arthritis), G6PD deficiency. Renal and hepatic impairment. Elderly, children. Pregnancy and lactation.
Store between 20-25°C.
Quinolones
Use on meds GO Class C; not approved for use in fast-track or non-fasting states.Use on meds Class C; not approved for use in fast-track or non-fasting states.
Use in pregnancy and women who are breastfeeding; includes combinations with other antacids, Fe or dairy products.
Ciprofloxacin is a broad-spectrum antibiotic commonly used to treat a variety of bacterial infections, including urinary tract infections (UTIs), respiratory tract infections (including septicemia), and skin and soft tissue infections. It can also be used to treat urinary tract infections in pets with bladder or kidney stones, as well as ear and nose infections.
This medication belongs to the fluoroquinolone class, which includes ciprofloxacin and other drugs for the treatment and prevention of bacterial infections. It is important to follow your veterinarian's instructions for use.
Common side effects of this medication include nausea, vomiting, diarrhea, and loss of appetite. These side effects are usually mild and temporary and tend to resolve on their own over time. However, it is important to consult with your veterinarian if these side effects continue or worsen.
Precautions and warnings
Do not use this medication if you are allergic to ciprofloxacin or other fluoroquinolone antibiotics, such as ciprofloxacin or levofloxacin. Contact your veterinarian immediately if you develop an allergic reaction such as skin rash, itching, or difficulty breathing. Tell your veterinarian if you are pregnant, plan to become pregnant, or are breast-feeding.
This medication should not be given to children under the age of 8 years, as it can harm their development. Use with caution in pets with liver or kidney disease.
Consult your veterinarian
Consult your veterinarian for a list of antibiotics that can interact with ciprofloxacin, as it may interact with the medication in some cases.
This medication may be affected by a number of other medications, such as warfarin, lithium, digoxin, rifampin, ritonavir, and some antibiotics.
Contact your veterinarian immediately if you notice any changes in your condition while on this medication.
Inform your veterinarian of all medications, supplements, and herbal products you are using to avoid potential interactions.
Ciprofloxacin should be stored at room temperature, away from moisture and direct sunlight. Keep all medications away from children and pets. Keep all drugs out of reach of children and pets.
This medication may be affected by alcohol, as it may cause side effects.
Contact your veterinarian
Follow all directions on your veterinarian's label and the direction on the package. The recommended dosage and duration of treatment for this medication is up to 4 weeks.
Ciprofloxacin should be given at the first sign of skin reaction or unusual bruising, rash, or discoloration of the skin or whites of the eyes. It is generally safe to use Ciprofloxacin for up to 6 weeks.
It is not recommended to give Ciprofloxacin to children under 8 years of age or in pets. Ciprofloxacin should be used with caution in pets with liver or kidney disease.
Ciprofloxacin may cause side effects in some individuals. It is important to inform your veterinarian of any other side effects or unusual reactions you may experience. Tell your veterinarian if you notice any of the following:
The most common side effects of Ciprofloxacin are:
Contact your veterinarian immediately if you develop a rash or other unusual skin changes while taking this medication.
Ciprofloxacin should be used with caution in pets with kidney disease or liver disease.
Generic name: Ciprofloxacin HCl
This medicine contains a synthetic salt form of ciprofloxacin HCl. It is used to treat infections caused by the following bacteria:
The brand names for ciprofloxacin hydrochloride salt are Ciprofloxacin (brand name: Cipro) and Lomefloxacin (brand name: Lome).
to use the medicine.
Take this medicine with or without food.
Take the dose as soon as you remember. Continue to take this medicine at the same time of day. Do not take the dose more often than directed. Swallow the tablets whole with a full glass of water. Do not crush or chew the tablets. The medicine is to be taken with or without food.
Some side effects of the medicine are very common. If you notice any of the following side effects, stop using this medicine and tell your doctor:
Do not use if you are allergic to ciprofloxacin or any of the other ingredients in the medicine. Also do not use this medicine if you have kidney disease. Do not use if you have kidney disease. Do not take ciprofloxacin if you have or have had a history of liver disease, including cirrhosis. Use the medicine with caution in pregnant women. If you are taking the medicine for infections, use it as directed, and tell your doctor or pharmacist if you are pregnant or may become pregnant.
Before taking the medicine, tell your doctor if you have or have ever had kidney stones, kidney problems, diabetes, a history of heart disease, or a heart attack, angina, high blood pressure, or a history of seizures.
Ciprofloxacin is a broad-spectrum antibiotic used to treat a wide range of bacterial infections. Ciprofloxacin is also used to treat anthrax. It works by interfering with the production of essential proteins in bacteria. Ciprofloxacin belongs to a group of antibiotics called tetracyclines. Ciprofloxacin is effective against a wide range of bacteria, including those that are resistant to other antibiotics. Ciprofloxacin is used to treat infections caused by a wide variety of bacteria, including respiratory, urinary, and skin infections. It works by blocking the production of the essential proteins needed to make bacteria.
Ciprofloxacin may also be used to treat a fungal infection such as ringworm. Ciprofloxacin may also be used to treat acne and other conditions where the immune system is weakened. Ciprofloxacin may also be used to prevent malaria. It is important to consult with a doctor before taking Ciprofloxacin to ensure it is the right medication for your infection.
Ciprofloxacin may cause side effects. Please consult your doctor if you have any questions. Please be aware that Ciprofloxacin is not suitable for everyone.
Stade de France Pharmacy